OTHERS AUTHORISATION AS DISTRIBUTOR OF WUHAN EASYDIAGNOSIS BIOMEDICINE CO. LTD. FOR COVID-19 NUCLEIC ACID TEST KIT AND NUCLEIC ACID EXTRACTION REAGENT
|HO WAH GENTING BERHAD|
AUTHORISATION AS DISTRIBUTOR OF WUHAN EASYDIAGNOSIS BIOMEDICINE CO. LTD. FOR COVID-19 NUCLEIC ACID TEST KIT AND NUCLEIC ACID EXTRACTION REAGENT
The Board of Directors wishes to announce that Ho Wah Genting Berhad (“HWGB” or the Company”) had on 3 April 2020 received a letter of authorisation dated 20 March 2020 from Wuhan Easydiagnosis Biomedicine Co. Ltd.(“WEBC”), for the authorisation of HWG Consortium Sdn Bhd (a wholly owned subsidiary of HWGB) as the distributor of its COVID-19 Nucleic Acid Test Kit and Nucleic Acid Extraction Reagent in Malaysia (“Products”) (“Authorisation”). The validity of the Authorisation is from 20 March 2020 to 20 March 2021.
Subsequently, the Company had also on 3 April 2020 submitted an application to the Ministry of Health, Malaysia for the certification of the Products.
Information on WEBC
WEBC (listed on Shenzhen Stock Exchange, Stock Code: 002932), with its principal place of business at Room 3, Factory (3), 1st Floor, Building 25, Phase 3.1 Wuhan Optics Valley International Biopharmaceutical Enterprise Accelerator, No. 388, Gaoxin 2nd Road, East Lake Hi-Tech Development Zone, 430074, Wuhan, Hubei, China is an In Vitro Diagnostics manufacturer, specialising in development, production and sales of point-of-care testing rapid diagnostic reagents and related equipment. WEBC is authorised to export medical products by Ministry of Commerce of the People's Republic of China.
This announcement is dated 3 April 2020.
|Company Name||HO WAH GENTING BERHAD|
|Date Announced||03 Apr 2020|
|Category||General Announcement for PLC|